Abstract

Neethu J.*, Alinta S. B. Muth, Christy Surendran, Anisha D. S. and Arya Rajan

ABSTRACT

Sodium glucose co-transporter (SGLT) 2inhibitors, called as ‘gliflozins’ are a relatively new class of oral hypoglycemic agents(OHA) approved by FDA in 2013 for use in type2 diabetes mellitus. These special class of OHAs induce glycosuria by reducing renal glucose reabsorption and thereby improve glycemic control. Apart from glucose lowering effect, other metabolic benefits are affirmated and safety concerns including 3 FDA drug safety communications issued in 2015.One of it was, Diabetic ketoacidosis,which occur in presence of low insulin levels, prolonged fasting or during stressful conditions. On May2015,USFDA declared the safety announcement that SGLT2 inhibitors such as Canagliflozin, Dapagliflozin, and Empagliflozin may cause ketoacidosis which may require emergency treatment. Investigations are continuing in this safety issue.These agents are still undergoing clinical studies concerning their safety and efficacy. This review is an effort to assess diabetic ketoacidosis as a safety concern associated with SGLT2 inhibition by going through past research studies, case reports and series.